Activity of cabazitaxel/gemcitabine plus pembrolizumab in heavily pretreated urothelial carcinoma

Vignesh Packiam, MD, urologist, assistant professor of Urology, University of Iowa Hospitals and Clinics, discusses the retrospective analysis, “Sequential endoluminal cabazitaxel and gemcitabine with pembrolizumab for docetaxel-unresponsive non-muscle invasive urothelial carcinoma of the upper and lower urinary tracts,” which he presented at the 2022 AUA Annual Meeting (abstract PD26-07).